Epidemiological and clinical aspects of the influence of hyperuricemia on the prognosis of cardiovascular and metabolic diseases

• Andrey G. Obrezan
• Anna A. Voevodina

Abstract

The article is devoted to the increasing clinical significance of hyperuricemia – elevated uric acid levels – in risk formation of occurrence and progression of cardiovascular and metabolic diseases. The authors note that hyperuricemia is an independent marker of worsening of cardiovascular diseases (CVD) and increased risks of their complications. Also, for several decades, it has been regarded by researchers as equivalent to cardiometabolic risk factors for CVD, such as hypercholesterolemia, hyperglycemia, and others. Different approaches to the treatment of hyperuricemia, depending on the level of uric acid and the presence of concomitant diseases, require attention. Based on the totality of data at the current stage, it is obvious that it is necessary to continue work on the formation of a comprehensive idea of an optimal point for initiation of antihyperuricemic therapy, which will obviously be in demand much earlier than the onset of cardiovascular, metabolic and nephrological complications.

Keywords: uric acid; hyperuricemia; cardiometabolic disorders; xanthine oxidase; cardiovascular risk

References

1. Karamnova N.S., Shal’nova S.A., Rytova A.I., Shvabskaya O.B., Makarova Yu.K., Balanova Yu.A., et al. Associations of dietary patterns and abdominal obesity in the adult population. Results of the Russian epidemiological ESSE-RF study. Rossiyskiy kardiologicheskiy zhurnal [Russian Journal of Cardiology]. 2021; 26 (5): 4363. DOI: https://doi.org/10.15829/1560-4071-2021-4363 (in Russian)

2. Verdecchia P., Schillaci G., Reboldi G.P., et al. The relation between serum uric acid and risk of cardiovascular disease in essential hypertension. The PIUMA study. Hypertension. 2000; 36: 1072–8.

3. Yanai H., Adachi H., Hakoshima M., Katsuyama H. Molecular biological and clinical understanding of the pathophysiology and treatments of hyperuricemia and its association with metabolic syndrome, cardiovascular diseases and chronic kidney disease. Int J Mol Sci. 2021; 22 (17): 9221. DOI: https://doi.org/10.3390/ijms22179221 PMID: 34502127; PMCID: PMC 8431537.

4. Biological chemistry with exercises and tasks: textbook. In corresponding member of RAS S.E. Severin (ed). 2011. 624 p.: ill.

5. Bowden R.G., Richardson K.A., Richardson L.T. Uric acid and metabolic syndrome: Findings from national health and nutrition examination survey. Front Med (Lausanne). 2022; 9: 1039230. DOI: https://doi.org/10.3389/fmed.2022.1039230 PMID: 36590930; PMCID: PMC 9795410.

6. Zhu Y., Pandya B.J., Choi H.K. Comorbidities of gout and hyperuricemia in the US general population: NHANES 2007–2008. Am J Med. 2012; 125: 679–87.e1. DOI: https://doi.org/10.1016/j.amjmed.2011.09.033

7. Maksimov S.A., Shal’nova S.A., Muromtseva G.A., Kapustina A.V., Imaeva A.E., Evstifeeva S.E., et al. Menopause and hyperuricemia in women in the russian population (results of the ESSE-RF study). Vestnik RAMN [Bulletin of the Russian Academy of Medical Sciences]. 2021; 76 (5): 449–57. DOI: https://doi.org/10.15690/vramn1455 (in Russian)

8. Brand F.N., Mcgee D.L., Kannel W.B., Stokes J., Castelli W.P. hyperuricemia as a risk factor of coronary heart disease: the Framingham study. Am J Epidemiol. 1985; 121 (1): 11–8.

9. Balanova Yu.A., Drapkina O.M., Kutsenko V.A., Imaeva A.E., Kontsevaya A.V., Maksimov S.A., et al. Obesity in the Russian population during the COVID-19 pandemic and associated factors. Data from the ESSE-RF3 study. Kardiovaskulyarnaya terapiya i profilaktika [Cardiovascular Therapy and Prevention]. 2023; 22 (8S): 3793. DOI: https://doi.org/10.15829/1728-8800-2023-3793 EDN: SBUNIG. (in Russian)

10. Kutishenko N.P., Martsevich S. Yu., Zagrebel’ny A.V., Lukina Yu.V., Voronina V.P., Dmitrieva N.A., et al. Detection and Treatment of Hyperuricemia in Clinical Practice (According to the PROFILE Outpatient Registry). Ratsional’naya farmakoterapiya v kardiologii [Rational Pharmacotherapy in Cardiology]. 2022; 18 (4): 449–54. DOI: https://doi.org/10.20996/1819-6446-2022-08-12 (in Russian)

11. Caliceti C., Calabria D., Roda A., Cicero A.F.G. Fructose intake, serum uric acid, and cardiometabolic disorders: a critical review. Nutrients. 2017; 9: 395. DOI: https://doi.org/10.3390/nu9040395

12. Copur S., Demiray A., Kanbay M. Uric acid in metabolic syndrome: does uric acid have a definitive role? Eur J Intern Med. 2022; 103: 4–12. DOI: https://doi.org/10.1016/j.ejim.2022.04.022 Epub 2022 May 1. PMID: 35508444.

13. Mahajan A., Mahajan A., Kotwal S., Tandon V.R. Relationship of hyperuricemia and metabolic syndrome. JK Sci. 2021; 23 (2): 94–7. URL: https://journal.jkscience.org/index.php/JK-Science/article/view/65 (date of access August 19, 2024).

14. Chen S., Yang H., Chen Y., Wang J., Xu L., Miao M., et al. Association between serum uric acid levels and dyslipidemia in Chinese adults: a cross-sectional study and further meta-analysis. Medicine (Baltimore). 2020; 99: e19088. DOI: https://doi.org/10.1097/MD.0000000000019088

15. Goli P., Riahi R., Daniali S.S., Pourmirzaei M., Kelishadi R. Association of serum uric acid concentration with components of pediatric metabolic syndrome: a systematic review and meta-analysis. J Res Med Sci. 2020; 25: 43.

16. Hjortnaes J., Algra A., Olijhoek J., Huisman M., Jacobs J., van der Graaf Y., Visseren F. Serum uric acid levels and risk for vascular diseases in patients with metabolic syndrome. J Rheumatol. 2007; 34: 1882–7.

17. Facchini F., Chen Y.D., Hollenbeck C.B., Reaven G.M. Relationship between resistance to insulin-mediated glucose uptake, urinary uric acid clearance, and plasma uric acid concentration. JAMA. 1991; 266: 3008–11. DOI: https://doi.org/10.1001/jama.1991.03470210076036

18. Cherenkevich T.V. Prevalence of hyperuricemia among patients with rheumatological profile [Electronic resource]. In: S.P. Rubnikovich, V.A. Filonyuk (eds). Actual Problems of Modern Medicine and Pharmacy 2022: Collection of Materials of Reports. LXXVI International Scientific and Practical Conference of Students and Young Scientists, Minsk, April 20–21, 2022. Minsk, 2022: 271–5. (in Russian)

19. Chazova I.E., Zhernakova Yu.V., Kislyak O.A., Podzolkov V.I., Oshchepkova E.V., Mironova O. Yu., et al. Consensus on patients with hyperuricemia and high cardiovascular risk treatment: 2022. Sistemnye gipertenzii [Systemic Hypertension]. 2022; 19 (1): 5–22. DOI: https://doi.org/10.38109/2075-082X-2022-1-5-22 (in Russian)

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)